Literature DB >> 18305393

Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar beta amyloid peptide (1-42)-stimulated microglia.

Ju Hyun Moon1, Soo Yoon Kim, Hwan Goo Lee, Seung U Kim, Yong Beom Lee.   

Abstract

Recent studies have reported that the cholinergic anti-inflammatory pathway regulates peripheral inflammatory responses via alpha7 nicotinic acetylcholine receptors (alpha7 nAChRs) and that acetylcholine and nicotine regulate the expression of proinflammatory mediators such as TNF-alpha and prostaglandin E2 in microglial cultures. In a previous study we showed that ATP released by beta-amyloid-stimulated microglia induced reactive oxygen species (ROS) production, in a process involving the P2X(7) receptor (P2X(7)R), in an autocrine fashion. These observations led us to investigate whether stimulation by nicotine could regulate fibrillar beta amyloid peptide (1-42) (fAbeta1-42)-induced ROS production by modulating ATP efflux-mediated Ca(2+) influx through P2X(7)R. Nicotine inhibited ROS generation in fAbeta(1-42)-stimulated microglial cells, and this inhibition was blocked by mecamylamine, a non-selective nAChR antagonist, and a-bungarotoxin, a selective alpha7 nAChR antagonist. Nicotine inhibited NADPH oxidase activation and completely blocked Ca(2+) influx in fAbeta(1-42)-stimulated microglia. Moreover, ATP release from fAbeta(1-42)-stimulated microglia was significantly suppressed by nicotine treatment. In contrast, nicotine did not inhibit 2',3'-O-(4-benzoyl)-benzoyl ATP (BzATP)-induced Ca(2+) influx, but inhibited ROS generation in BzATP-stimulated microglia, indicating an inhibitory effect of nicotine on a signaling process downstream of P2X(7)R. Taken together, these results suggest that the inhibitory effect of nicotine on ROS production in fAbeta1-42-stimulated microglia is mediated by indirect blockage of ATP release and by directly altering the signaling process downstream from P2X(7)R.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305393      PMCID: PMC2679317          DOI: 10.3858/emm.2008.40.1.11

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  30 in total

Review 1.  Acetylcholine, aging, and Alzheimer's disease.

Authors:  J L Muir
Journal:  Pharmacol Biochem Behav       Date:  1997-04       Impact factor: 3.533

2.  Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role.

Authors:  Tomohisa Suzuki; Izumi Hide; Akiyo Matsubara; Chihiro Hama; Kana Harada; Kanako Miyano; Matthias Andrä; Hiroaki Matsubayashi; Norio Sakai; Shinichi Kohsaka; Kazuhide Inoue; Yoshihiro Nakata
Journal:  J Neurosci Res       Date:  2006-06       Impact factor: 4.164

3.  Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Alzheimers Dis       Date:  2006-07       Impact factor: 4.472

Review 4.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

Review 6.  Nicotine addiction: the possible role of functional upregulation.

Authors:  Bruno Buisson; Daniel Bertrand
Journal:  Trends Pharmacol Sci       Date:  2002-03       Impact factor: 14.819

Review 7.  Neuronal nicotinic receptors: from structure to pathology.

Authors:  C Gotti; F Clementi
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

8.  Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain.

Authors:  P L McGeer; E G McGeer; J Suzuki; C E Dolman; T Nagai
Journal:  Neurology       Date:  1984-06       Impact factor: 9.910

9.  Interleukin-10 expression in lipopolysaccharide-activated microglia is mediated by extracellular ATP in an autocrine fashion.

Authors:  Dong Reoyl Seo; Kyung You Kim; Yong Beom Lee
Journal:  Neuroreport       Date:  2004-05-19       Impact factor: 1.837

10.  Glial cells express multiple ATP binding cassette proteins which are involved in ATP release.

Authors:  Patrizia Ballerini; Patrizia Di Iorio; Renata Ciccarelli; Eleonora Nargi; Iolanda D'Alimonte; Ugo Traversa; Michel P Rathbone; Francesco Caciagli
Journal:  Neuroreport       Date:  2002-10-07       Impact factor: 1.837

View more
  24 in total

Review 1.  Microglia antioxidant systems and redox signalling.

Authors:  F Vilhardt; J Haslund-Vinding; V Jaquet; G McBean
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

2.  Sinomenine inhibits microglial activation by Aβ and confers neuroprotection.

Authors:  Shilpa Mishra Shukla; Shiv K Sharma
Journal:  J Neuroinflammation       Date:  2011-09-14       Impact factor: 8.322

Review 3.  NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease.

Authors:  J Haslund-Vinding; G McBean; V Jaquet; F Vilhardt
Journal:  Br J Pharmacol       Date:  2016-02-26       Impact factor: 8.739

4.  ZY-1, a novel nicotinic analog, promotes proliferation and migration of adult hippocampal neural stem/progenitor cells.

Authors:  Na He; Zejian Wang; Yin Wang; Hanlin Shen; Ming Yin
Journal:  Cell Mol Neurobiol       Date:  2013-09-22       Impact factor: 5.046

5.  Cryptotanshinione inhibits β-amyloid aggregation and protects damage from β-amyloid in SH-SY5Y cells.

Authors:  Zhengrong Mei; Pengke Yan; Bing Situ; Yonggao Mou; Peiqing Liu
Journal:  Neurochem Res       Date:  2011-11-19       Impact factor: 3.996

6.  Cardiopulmonary arrest and resuscitation disrupts cholinergic anti-inflammatory processes: a role for cholinergic α7 nicotinic receptors.

Authors:  Greg J Norman; John S Morris; Kate Karelina; Zachary M Weil; Ning Zhang; Yousef Al-Abed; Holly M Brothers; Gary L Wenk; Valentin A Pavlov; Kevin J Tracey; A Courtney Devries
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

Review 7.  Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases.

Authors:  Merouane Bencherif; Patrick M Lippiello; Rudolf Lucas; Mario B Marrero
Journal:  Cell Mol Life Sci       Date:  2010-10-15       Impact factor: 9.261

8.  Neuroprotective and antioxidative effect of cactus polysaccharides in vivo and in vitro.

Authors:  Xianju Huang; Qin Li; Huige Li; Lianjun Guo
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

Review 9.  Astrocytic and microglial nicotinic acetylcholine receptors: an overlooked issue in Alzheimer's disease.

Authors:  Saeed Sadigh-Eteghad; Alireza Majdi; Javad Mahmoudi; Samad E J Golzari; Mahnaz Talebi
Journal:  J Neural Transm (Vienna)       Date:  2016-06-04       Impact factor: 3.575

Review 10.  Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors.

Authors:  Michael J Surace; Michelle L Block
Journal:  Cell Mol Life Sci       Date:  2012-05-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.